CDC Panel Revises Hepatitis B Vaccine Recommendations for Newborns
The CDC's Advisory Committee on Immunization Practices has voted to change the longstanding recommendation for universal hepatitis B vaccination at birth, now advising that only infants born to hepatitis B-positive mothers receive the vaccine immediately after birth.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has voted 8-3 to revise the longstanding recommendation that all newborns receive the hepatitis B vaccine at birth. The new guidance advises that only infants born to mothers who test positive for hepatitis B should receive the vaccine immediately after birth. For infants whose mothers test negative or whose status is unknown, the recommendation is to consult with healthcare providers about vaccination, with the possibility of delaying the first dose until at least two months of age.
This decision has drawn criticism from public health experts who emphasize that the universal birth dose policy, in place since 1991, has significantly reduced hepatitis B cases among children. Dr. Grant Paulsen, representing the Pediatric Infectious Diseases Society, questioned the rationale behind changing a policy that has been effective for decades, citing concerns that the proposed changes are based on theoretical safety concerns rather than concrete evidence.
The ACIP's recommendation now awaits approval from the CDC's acting director. If adopted, this would mark a significant shift in U.S. vaccination policy, potentially impacting the incidence of hepatitis B among children nationwide.